Shijiazhuang Yiling Pharmaceutical Co., Ltd.
002603
Pozycja w akcjach
#4267
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and... Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Cena akcji
$2.29
Kapitalizacja rynkowa
$3.83B
Zmiana (1 dzień)
3.06%
Zmiana (1 rok)
-6.38%
Kraj
CN
Handel Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603)
Kategoria
Healthcare
Wskaźnik P/B dla Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603)
Wskaźnik P/B na dzień October 2026 TTM: 2.30
Według najnowszych raportów finansowych i ceny akcji Shijiazhuang Yiling Pharmaceutical Co., Ltd., obecny wskaźnik P/B (TTM) wynosi 2.30. Na koniec 2023 wynosił 3.37.
Historia wskaźnika P/B dla Shijiazhuang Yiling Pharmaceutical Co., Ltd. od 2008 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 2.30 | -12.10% |
| 2024 | 2.62 | -22.28% |
| 2023 | 3.37 | -26.48% |
| 2022 | 4.58 | 26.81% |
| 2021 | 3.61 | 5.85% |
| 2020 | 3.41 | 82.65% |
| 2019 | 1.87 | 19.92% |
| 2018 | 1.56 | -36.50% |
| 2017 | 2.45 | -31.76% |
| 2016 | 3.59 | -13.52% |
| 2015 | 4.16 | 17.24% |
| 2014 | 3.54 | -17.08% |
| 2013 | 4.27 | 29.26% |
| 2012 | 3.31 | -17.86% |
| 2011 | 4.03 | -70.70% |
| 2010 | 13.74 | -26.60% |
| 2009 | 18.72 | -38.84% |
| 2008 | 30.61 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 3.8424 | 66.84% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| 17.3539 | 653.53% |
US
|
|
| - | - |
IT
|
